DPP-4 resistance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
=== Dry granular flows === Under certain circumstances, flows of granular materials can be modelled as a continuum, for example using the μ(I) rheology. Such continuum models tend to be non-Newtonian, since the apparent viscosity of granular flows increases with pressure and decreases with shear rate. The main difference is the shearing stress and rate of shear.
During the 2026 AFL Season, Essendon parted ways with senior coach Brad Scott, despite him having a year remaining on his contract. The Club's board cited a "lack of progress" and failure to meet key performance indicators as the primary reasons for his termination. This decision followed a severe downturn in on-field performance, in which the Bombers recorded only one victory from a 24-game period, spanning the 2025 and 2026 Seasons. Following Brad Scott's departure, assistant coach Dean Solomon was appointed interim senior coach for the remainder of the season.
== Criticisms and controversies == The war on drugs has faced increasingly intense criticism as its failures have become more apparent throughout the years, both from formal and informal establishments. The war on drugs is generally accepted to be a policy failure. It has failed to decrease the number of drugs flowing into the United States or internationally; it has also failed to decrease the number of drug users in the United States. The US government estimates it has spent around $1 trillion on combating the drug war. Despite this, drug use has either continued to stay stagnant or continued to grow. One report found a 26% increase in overall drug use from 2010 to 2020; another found that cocaine use in the US has consistently stayed at around 1.5-2 million users since the 1990s. Drug use is therefore either staying stagnant at least, or even increasing. Attempts to cut off the drug trade at its source have overwhelmingly failed, and violent organised crime in the south and central American countries has increased dramatically. Millions have died, primarily in Central and South America, as a result of the violence associated with the illicit drug trade. Prohibition has resulted in high incarceration rates in the United States, something which has disproportionately impacted black communities.
exenatide (brand names Byetta and Bydureon, manufactured by AstraZeneca), approved 2005/2012, discontinued in 2024 albiglutide (Tanzeum, manufactured by GSK), approved in 2014, discontinued in 2017 lixisenatide (Lyxumia in Europe, Adlyxin in the United States, manufactured by Sanofi), approved in 2016, discontinued in 2023
Sources: en.wikipedia.org
Collagen α-1 (XXIII) chain is a protein encoded by COL23A1 gene, which is located on chromosome 5q35 in humans, and on chromosome 11B1+2 in mice. The location of this gene was discovered by genomic sequence analysis. Collagen XXIII is a type II transmembrane protein and the fourth in the subfamily of non-fibrillar transmembranous collagens. This kind of collagens have a single pass hydrophobic transmembrane domain. The molecule of collagen XXIII can be found either in membrane-bond form or in shed form. Type XXIII collagen is expressed in both adult tissues and developing organs. It can be found in the epidermis and other epithelia such as those in tongue, gut and lung, but also in the brain, the kidney and the cornea. It has been shown that in prostate collagen XXIII expression is associated with tumor progression. The functions of collagen XXIII are still unknown, although it is believed that they could be similar to other transmembrane proteins, such as collagen XIII.
== History of the taxonomy == Prior to 1993, the family Conidae contained only Conus species. In 1993 significant taxonomic changes were proposed by Taylor, et al.,: the family Conidae was redefined as several subfamilies. The subfamilies included many subfamilies that had previously been classified in the family Turridae, and the Conus species were moved to the subfamily Coninae. In further taxonomic changes that took place in 2009 and 2011, based upon molecular phylogeny (see below), the subfamilies that were previously in the family Turridae were elevated to the status of families in their own right. This left the family Conidae once again containing only those species that were traditionally placed in that family: the cone snail species.
The Gam-COVID-Vac vaccine was developed by a cellular microbiologists team of the government-backed Gamaleya Research Institute of Epidemiology and Microbiology. The group was led by MD and RAS associate member Denis Logunov, who also worked on vaccines for the Ebolavirus and the MERS-coronavirus. In May 2020, the Gamaleya Research Institute of Epidemiology and Microbiology announced that it had developed the vaccine without serious side effects. By August 2020, phases I and II of two clinical trials (involving 38 patients each) were completed. Only one of them used the formulation which later obtained marketing authorization under limited conditions. This vaccine was given the trade name "Sputnik V", after the world's first artificial satellite. During preclinical and clinical trials, 38 participants who received one or two doses of the Gam-COVID-Vac vaccine had produced antibodies against SARS-CoV-2's spike protein, including potent neutralizing antibodies that inactivate viral particles. On 11 August 2020, the Russian minister of Health Mikhail Murashko announced at a government briefing with the participation of President Vladimir Putin regulatory approval of the vaccine for widespread use. The state registration of the vaccine was carried out "conditionally" with post-marketing measures according to the decree of the Government of the Russian Federation.
Shadrake's book highlighted the contrasting fortunes of German citizen Julia Suzanne Bohl, who ran a major drug ring catering to well off professionals and was herself caught with a capital amount (over 500 grams) of cannabis when police raided her apartment, to Singaporean drug addict Yen May Woen who was caught in possession of 30 grams of low quality heroin. While Bohl had her charges reduced after German diplomatic pressure was allegedly applied amidst much media coverage of her plight and returned to Germany after 3 years imprisonment, the case of Woen received very little coverage in the local newspapers and she was executed after the trial judge handed down the mandatory death sentence. Shadrake was arrested whilst promoting the book in Singapore and later sentenced to six weeks in prison for contempt of court. He is also charged with criminal defamation. The case attracted worldwide attention, putting the Singapore legal system in the spotlight. Shadrake apologised to the court if he had offended the sensitivities of the judiciary and did not mean to undermine the judges or the judiciary, but stood by his book, apart from a mistake contained within. The judge, Quentin Loh, dismissed his apology as "nothing more than a tactical ploy in court to obtain a reduced sentence". Shadrake's conviction for scandalising the court was upheld by the Court of Appeal.
== External links == The MEROPS online database for peptidases and their inhibitors: I35.001 Overview of all the structural information available in the PDB for UniProt: P01033 (Metalloproteinase inhibitor 1) at the PDBe-KB.
Sources: en.wikipedia.org
Without treatment, physical deformities occur in 10% of cases. Yaws is common in at least 13 tropical countries as of 2012. Almost 85% of infections occurred in three countries—Ghana, Papua New Guinea, and Solomon Islands. The disease only infects humans. Efforts in the 1950s and 1960s by the World Health Organization decreased the number of cases by 95%. Since then, cases have increased, but with renewed efforts to globally eradicate the disease by 2020. In 1995, the number of people infected was estimated at more than 500,000. In 2016, the number of reported cases was 59,000. Although one of the first descriptions of the disease was made in 1679 by Willem Piso, archaeological evidence suggests that yaws may have been present among human ancestors as far back as 1.6 million years ago.
=== Resale status === As a result of earlier unauthorized sales to civilians, the Department of Defense requires that "U.S. Government Property, Commercial Resale is Unlawful" be printed on each case of MREs. The warning is only intended for service members, as there are no laws that forbid the resale of MREs by civilians. Although the government has attempted to discourage sellers from selling MREs, auction sites such as eBay have continued to allow auctions of the MREs because the Department of Defense has been unable to provide any regulations or laws specifically outlawing the practice. According to a spokesman for eBay, "until a law is passed saying you can't sell these things, we're not going to stop them from being sold on the site." Therefore, while MREs are not prima facie contraband, the procurement and sale of MREs by military personnel for personal profit is illegal under the Uniform Code of Military Justice Article 108. As a result, MREs found for sale outside reputable vendors often fall into a grey market where the question of how it entered civilian hands (through theft/legitimate means) and/or its quality may be unknown. An investigation conducted in 2006 on behalf of the U.S. Government Accountability Office (GAO) determined multiple instances where sellers on eBay may have improperly obtained MREs and sold them to the public for private gain. As military MREs are procured at taxpayers' expense, they are intended to be consumed by individuals from authorized organizations and activities.
== Works == Newsom, Gavin; Dickey, Lisa (February 7, 2013). Citizenville: How to Take the Town Square Digital and Reinvent Government. Penguin. ISBN 978-1101605813. Newsom, Gavin (February 24, 2026). Young Man in a Hurry: A Memoir of Discovery. Penguin. ISBN 978-1984881939.
== Use and effects == The 25-NB drugs are inactive orally and instead are typically used sublingually, buccally, by insufflation, or sometimes via inhalation. They are typically employed at doses in the range of 50 to 1,500 μg, variable depending on the specific drug, and have durations in the range of 3 to 12 hours. The table below provides an overview of the major 25-NB drugs and their properties. Conventionally, 25-NB have been known to be orally inactive due to extensive first-pass metabolism. However, an orally active N-benzylphenethylamine with an atypical chemical structure known as BMB-202 has since been identified and is under development for potential medical use. It is predicted to have a fast onset and a short duration of 1 to 2 hours in humans.
== Biological role and synthesis == Two archaeol molecules can undergo head-to-head linkage to form caldarchaeol (one typical glycerol dialkyl glycerol tetraether, GDGT), one of the most common tetraether lipids in archaea.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.